<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122879">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02144272</url>
  </required_header>
  <id_info>
    <org_study_id>15098</org_study_id>
    <secondary_id>I6W-MC-TNAA</secondary_id>
    <nct_id>NCT02144272</nct_id>
  </id_info>
  <brief_title>Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis</brief_title>
  <official_title>A Phase 1 Single-Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of LY3114062 in Subjects With Inflammatory Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Bulgaria: Ethics committee</authority>
    <authority>Moldova: Medicines Agency</authority>
    <authority>Moldova: Ministry of Health</authority>
    <authority>Moldova: National Ethics Committee</authority>
    <authority>Romania: National Bioethics Committee of Medicines and Medical Devices</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Netherlands:  Independent Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3114062 and to find
      out how well it is tolerated in participants with an inflammatory arthritis.  The study will
      also investigate how the body processes the drug and how the drug affects inflammatory
      arthritis.  The study is expected to last about 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>The Number of Participants with One or More Drug-Related Adverse Events</measure>
    <time_frame>Baseline to study completion (3 months)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY3114062</measure>
    <time_frame>Predose through Day 85, at specified timepoints</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-time curve (AUC) of LY3114062</measure>
    <time_frame>Predose through Day 85, at specified timepoints</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Production Against LY3114062</measure>
    <time_frame>Day 1, 8, 15, 29, 85 and early discontinuation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Inflammatory Arthritis</condition>
  <arm_group>
    <arm_group_label>LY3114062 (SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3114062 given as a single subcutaneous (SC) dose, in escalating dose cohorts starting at 2 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3114062 (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3114062 given once intravenous (IV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (sodium chloride injection) given as a single SC dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3114062 SC</intervention_name>
    <description>LY3114062 administered SC.</description>
    <arm_group_label>LY3114062 (SC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered SC.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3114062 IV</intervention_name>
    <description>LY3114062 administered IV.</description>
    <arm_group_label>LY3114062 (IV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signs or symptoms of an inflammatory arthritis for a duration of at least 8 weeks at
             screening.

          -  Presence of at least 3 out of 66 swollen joints at screening and baseline, as
             determined by the swollen joint count assessment forms.  At least 1 of the swollen
             joints must be located in the hands, wrists, or forefeet and be corroborated by
             evidence of active synovitis on magnetic resonance imaging (MRI) at screening.

          -  Screening high-sensitivity C-reactive protein &gt;0.6 milligrams per deciliter (mg/dL)
             as measured by the central laboratory.

        Exclusion Criteria:

          -  Any prior treatment with an oral disease-modifying anti-rheumatic drug (DMARD) for 12
             weeks or longer.

          -  Treatment with any oral DMARD (eg, hydroxychloroquine, methotrexate, sulfasalazine,
             gold salts) within 28 days prior to screening.  For leflunomide, the washout period
             before randomization must be a minimum of 12 weeks (or a minimum of 4 weeks after 11
             days of standard cholestyramine washout).

          -  Any prior treatment with biologic DMARDs (including but not limited to
             TNF-inhibitors, tocilizumab, abatacept, rituximab) or any investigational
             antirheumatic agent (including ixekizumab). Prior or current use of other biologics
             for indications other than an inflammatory arthritis may be allowed with sponsor
             approval.

          -  Treatment with &gt;10 mg/day, or unstable dose, of oral prednisone or equivalent within
             28 days prior to screening.

          -  Confirmed or suspected septic arthritis, crystal arthropathy, systemic lupus
             erythematosus, reactive arthritis, or certain other rheumatic conditions.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lieden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody</keyword>
  <keyword>Tumor Necrosis Factor alpha</keyword>
  <keyword>Interleukin-17</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
